This conference will provide crucial guidance and relevant updates on all of the key issues affecting pharmaceutical lifecycles in Europe and internationally.
As the area of pharmaceutical patent lifecycles becomes increasingly complex, with pharmaceutical products fast approaching a “patent cliff,” it is estimated that in 2015 $47.5 billion of lost sales affected the industry overall. It is critical for pharmaceutical companies to capitalise on their R&D expenditure by obtaining Supplementary Protection Certificates in Europe, but there are also other legal and technical ways to extend patent terms in Europe and around the world.
This conference will explore a range of topical issues to ensure you are in the best possible position to extend your patent lifecycles. Sessions covered will include the evolving landscape of SPC regulation, the impact of the latest case law application on SPCs, and the extent of patent protection for Pharmaceutical inventions. It will also provide you with the implementable tools to extend your patents’ lifecycle in those countries which do not offer patent term extensions, offering you exclusive updates in critical markets, as well as digging deeper into the impact of TPP on patent term extensions.
Delivered by established and highly reputable experts from the pharmaceutical and legal industry, this is a must attend Forum for in-house and private practice patent attorneys and lawyers to gather and share the latest information on SPCs’ case law and best practices and strategies to extend the protection given by their patents.
Participants will receive a comprehensive set of valuable materials prepared by the speakers specifically for this event. These are materials that you will be able to use again and again.
Wednesday, June 22, 2016
15th International Forum on Pharmaceutical Patent Term Extensions, C5 Conferences
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.